420 related articles for article (PubMed ID: 17683587)
1. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
[TBL] [Abstract][Full Text] [Related]
2. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Yoneda KY; Shelton DK; Beckett LA; Gandara DR
J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
[TBL] [Abstract][Full Text] [Related]
3. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
4. New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.
Taj A; Kanjwal S; Hammersley JR
Am J Ther; 2011 Jan; 18(1):e19-21. PubMed ID: 20019587
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
6. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary toxicity associated with erlotinib.
Liu V; White DA; Zakowski MF; Travis W; Kris MG; Ginsberg MS; Miller VA; Azzoli CG
Chest; 2007 Sep; 132(3):1042-4. PubMed ID: 17873198
[TBL] [Abstract][Full Text] [Related]
8. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
Johkoh T; Sakai F; Kusumoto M; Arakawa H; Harada R; Ueda M; Kudoh S; Fukuoka M
Clin Lung Cancer; 2014 Nov; 15(6):448-54. PubMed ID: 25043209
[TBL] [Abstract][Full Text] [Related]
9. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
[TBL] [Abstract][Full Text] [Related]
10. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
ter Heine R; van den Bosch RT; Schaefer-Prokop CM; Lankheet NA; Beijnen JH; Staaks GH; van der Westerlaken MM; Malingré MM; van den Brand JJ
Lung Cancer; 2012 Mar; 75(3):391-7. PubMed ID: 22101147
[TBL] [Abstract][Full Text] [Related]
11. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
Atagi S; Katakami N; Yoshioka H; Fukuoka M; Kudoh S; Ogiwara A; Imai M; Ueda M; Matsui S
Clin Lung Cancer; 2013 Jul; 14(4):407-17. PubMed ID: 23490546
[TBL] [Abstract][Full Text] [Related]
12. [Fatal interstitial lung disease associated with erlotinib use].
Eshuis M; Ahsmann EJ; van Egmond NH
Ned Tijdschr Geneeskd; 2013; 157(7):A5519. PubMed ID: 23406641
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.
Chou CL; Ko HW; Wang CW; Yu CT; Kuo HP; Huang CD
Chang Gung Med J; 2010; 33(1):100-5. PubMed ID: 20184801
[TBL] [Abstract][Full Text] [Related]
14. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
15. [Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].
Wu X; Gao G; Ren S; Zhou C
Zhongguo Fei Ai Za Zhi; 2012 Aug; 15(8):494-8. PubMed ID: 22901999
[TBL] [Abstract][Full Text] [Related]
16. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review.
Macerelli M; Mazzer M; Foltran L; Cardellino GG; Aprile G
Tumori; 2015 Jul; 101(4):e122-7. PubMed ID: 25953445
[TBL] [Abstract][Full Text] [Related]
20. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Niho S; Goto K; Yoh K; Kim YH; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Jpn J Clin Oncol; 2006 May; 36(5):269-73. PubMed ID: 16702163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
